AstraZeneca to reissue Covid-19 vaccine trial data after monitors raise alarm

AstraZeneca said it would reissue key data on its American clinical trial “within 48 hours” after the independent monitoring board that oversaw the study warned US authorities that results released by the company on Monday were misleading.